Strategic Acquisition Impact TSO3 was acquired by Stryker in 2019 for CAD 68.4MM (USD 51.7MM), indicating a strong exit event and potential integration channel. Sales teams should explore opportunities with Stryker’s extended medical devices portfolio or identify alternative strategic buyers who value low-temperature sterilization for heat-sensitive devices.

Low-Temperature Sterilization Advantage The company focuses on a unique low-temperature sterilization technology for heat-sensitive medical devices, positioning it in a high-growth, technically differentiated segment. Target manufacturers of complex devices (catheters, implants, and minimally invasive tools) that require compatible sterilization processes.

Strategic Partnerships Historical collaborations with Mount Sinai and ongoing clinical demonstrations suggest a pathway for partnerships and pilots with large health systems. Sales opportunities exist in securing additional deployment agreements with academic medical centers and integrated delivery networks.

Global Reach Potential With offices in Quebec and Myrtle Beach and TSX listing, there is an international market opportunity to expand beyond Canada and the U.S. toward global medical device manufacturers seeking compliant sterilization solutions and potential co-development deals.

Financial Levers Current revenue is modest (1M–10M) with total funding at 20M, indicating room for growth through scaled deployments, volume-based pricing, and favorable ROI messaging for sterilization cost-per-cycle. Emphasize value propositions around reduction in sterilization cycles, device usability, and hospital throughput.